Results 81 to 90 of about 12,625 (176)

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective

Drugs - Real World Outcomes
Background and objectives Nirmatrelvir/ritonavir was administered orally to manage mild to moderate symptoms of COVID-19 in adult patients. The objectives of this study were to (i) evaluate the cost-effectiveness of prescribing nirmatrelvir/ritonavir ...
Ee Vien Low, Hoon Shien Teh, Nicholas Yee Liang Hing, Suresh Kumar Chidambaram, Mohan Dass Pathmanathan, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +14 more
doaj   +1 more source

Nirmatrelvir and ritonavir combination against COVID‐19 caused by omicron BA.2.2 in the elderly: A single‐center large observational study

Immunity, Inflammation and Disease
Background Since coronavirus 2019 (COVID‐19) swept the world, a variety of novel therapeutic and prevention strategies have been developed, among which nirmatrelvir–ritonavir is highly recommended.
Can Chen, Ranyi Li, Shuliang Xing, Lei Cao, Yue Qu, Qianzhou Lv, Xiaoyu Li, Zhangzhang Chen   +7 more
doaj   +1 more source

A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions

Cardiology Discovery
. With the increasing use of nirmatrelvir-ritonavir in older COVID-19 patients, adverse drug reactions due to drug-drug interactions have become more frequent.
Zhiqing Fu, Yan Guo, Shuai Li, Yang Shi, Hanjia Gao   +4 more
doaj   +1 more source

COVID-19 hospitalization risk after outpatient nirmatrelvir/ritonavir use, January to August 2022, North Carolina

In the USA, nirmatrelvir/ritonavir is authorized for the treatment of mild-to-moderate COVID-19 in patients at least 12 years of age, at high risk for progression to severe COVID-19.To estimate the impact of outpatient nirmatrelvir/ritonavir on COVID-19 ...
Napravnik, Sonia, Henderson, Heather I, Browne, Lindsay E, van Duin, David, Agil, Deana M, Li, Kuo-Ping, Wohl, David A, Fischer, William A, Eron, Joseph J, Bartelt, Luther A, Moy, Amanda   +10 more
core   +1 more source

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19

Frontiers in Pharmacology
Patients with systemic autoimmune rheumatic diseases are at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and effective antiviral treatments including nirmatrelvir/ritonavir can improve their outcomes.
Wei Zhang, Wei Zhang, Xingguo Zhang, Xingguo Zhang, Jinming Han, Wen Zhang, Jiarui Xu, Jiarui Xu, Xin Zhang, Hongjun Bian, Chong Meng, Deya Shang, Yi Zhou, Dawei Wang, Baobao Feng, Baobao Feng   +15 more
doaj   +1 more source

Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice

European Cardiology Review
Cardiovascular disease is associated with progression to severe COVID-19 and patients with the condition are among those in whom early antiviral therapy should be warranted.
Andrea Di Lenarda, Nicola Ferri, Massimiliano Lanzafame, Eva Agostina Montuori, Luciano Pacelli   +4 more
doaj   +1 more source

Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis

Tungs’ Medical Journal
Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly reduced the risk of coronavirus disease 2019 (COVID-19)-related ...
Chienhsiu Huang, Sufang Kuo, Lichen Lin
doaj   +1 more source

Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study:a target trial emulation study [PDF]

Background: Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the outcome of patients with mild-to-moderate COVID-19 symptoms.
Wong, Ian Chi Kei, Chan, Esther Wai Yin, Wan, Eric Yuk Fai, Yuen, Kwok Yung, Choi, Ming Hong, Hung, Ivan Fan Ngai, Chu, Wing Ming, Tam, Anthony Raymond   +7 more
core   +1 more source

An Intersectional Analysis of Social Deprivation and Patient Characteristics on Nirmatrelvir-Ritonavir for Treatment of COVID-19 in U.S. Primary Care Practices, 2021 to 2023

Journal of Primary Care & Community Health
Objective: Calculate rates of nirmatrelvir-ritonavir prescription and assess area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir for the treatment of COVID-19.
Esther E. Velásquez, Neil S. Kamdar, Nathaniel Hendrix, Xiaoyu Wang, Robert L. Phillips, David H. Rehkopf   +5 more
doaj   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study

BMC Infectious Diseases
Background Two oral antivirals for treatment of COVID-19 are available in Australia, nirmatrelvir-ritonavir, which is recommended, and molnupiravir, which is approved for use when nirmatrelvir-ritonavir is contraindicated.
Laura J. Edwards, Anish Scaria, Allen C. Cheng, Janaki Amin, Elizabeth J. Robinson, Caroline Sumpton, Bette Liu   +6 more
doaj   +1 more source